Skip to main content
SpringerLink
Log in
Book cover

Paravasation von Zytostatika pp 167–171Cite as

5-Fluorouracil (z.B. 5-Fluorouracil „Ebewe“)

  • Chapter

  • 21 Accesses

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Primärliteratur

  1. Cathcart-Rake WF, Mowery WE: Intrapericardial infusion of 5-fluorouracil. Cancer 67: 735–737, 1991.

    Article  PubMed  CAS  Google Scholar 

  2. Rodier JM, Malbec L, Lauraine EP, et al: Mediastinal infusion of epirubicin and 5-fluorouracil. A complication of totally implantable central venous systems. Report of a case. J Cancer Res Clin Oncol 122: 566–567, 1996.

    Article  PubMed  CAS  Google Scholar 

  3. Teta JB, O’Connor L: Local tissue damage from 5-fluorouracil extravasation. Oncol Nurs Forum 11: 77, 1984.

    PubMed  CAS  Google Scholar 

  4. Ross WB, Morris DL, Clingan PR: Major upper gastrointestinal haemorrhage associated with hepatic arterial chemoperfusion. Aust N Z J Surg 66: 816–819, 1996.

    Article  PubMed  CAS  Google Scholar 

  5. Manheimer F, Aranda CP, Smith RL: Necrotizing pneumonitis caused by 5-fluorouracil infusion. Cancer 70: 554–556, 1992.

    Article  PubMed  CAS  Google Scholar 

  6. Bertelli G, Gozza A, Forno GB, et al: Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13: 2851–2855, 1995.

    PubMed  CAS  Google Scholar 

  7. Reed WP, Newman KA, Applefeld MM, et al: Drug extravasation as a complication of venous access ports. Ann Intern Med 102: 788–790, 1985.

    Article  PubMed  CAS  Google Scholar 

  8. Seyfer AE, Solimando DA: Toxic lesions of the hand associated with chemotherapy. J Hand Surg 8: 39–42, 1983.

    Article  CAS  Google Scholar 

  9. Hrushesky WJ: Serpentine supravenous 5-fluorouracil (NSC-19893) hyper-pigmentation. Cancer Treat Rep 60: 639, 1976.

    PubMed  CAS  Google Scholar 

  10. Pujol RM, Rocamora V, Lopez-Pousa A, et al: Persistent supravenous erythematous eruption: a rare local complication of intravenous 5fluorouracil therapy. J Am Acad Dermatol 39: 839–842, 1998.

    Article  PubMed  CAS  Google Scholar 

Sekundürliteratur

  1. Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.

    Article  PubMed  CAS  Google Scholar 

  2. Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxic-drug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.

    PubMed  CAS  Google Scholar 

  3. Krämer I: Zytostatika-Paravasate-Set. Krankenhauspharmazie 13: 154–160, 1992.

    Google Scholar 

  4. Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.

    Google Scholar 

  5. Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6. Auflage: 1–17, 1999.

    Google Scholar 

  6. Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (Hrsg) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, Band 1, 2. Auflage: A42–44, 1997.

    Google Scholar 

  7. Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.

    Google Scholar 

  8. Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.

    Article  PubMed  CAS  Google Scholar 

  9. Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.

    PubMed  CAS  Google Scholar 

  10. Berdel WE, Schmoll HJ, Büchele T, et al: Prävention und Therapie von Paravasaten/Extravasaten. In: Schmoll HJ, Höffken K, Possinger K (Hrsg) Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Springer, Teil 1, 3. Auflage: 1689–1701, 1999.

    Google Scholar 

  11. Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.

    Google Scholar 

  12. Gain M. Melzer S, Meyer-Jürshof A, et al: Fluorouracil: Behandlung von Paravasaten. In: Gain M, et al (Hrsg) ADKA-Zytostatika-Handbuch, Pharmazeutisch-wissenschaftliche Monographien. Verlag Heiner Biller, Band 1, 2. Auflage: 57, 1997.

    Google Scholar 

  13. Barth J: Paravasate und deren Behandlung. In: Barth J (Hrsg) ZytostatikaHerstellung in der Apotheke. Deutscher Apotheker Verlag, Kap. VI-3: 1–9, 2000.

    Google Scholar 

  14. Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Austrian Breast and Colorectal Cancer Study Group, Wien, Österreich

    Dr. Ines Mader

  2. SMZ Floridsdorf, Krankenhaus und Geriatriezentrum, Wien, Österreich

    Mag. pharm. Patrizia Fürst-Weger

  3. Univ.-Klinik für Innere Medizin I, Klinische Abteilung für Onkologie, Wien, Österreich

    Univ.-Prof. Dr. Robert M. Mader

  4. Anstaltsapotheke, Landeskrankenhaus — Universitätskliniken Innsbruck, Wien, Österreich

    Mag. pharm. Dr. Elisabeth I. Semenitz

  5. Apotheke der Krankenanstalt Rudolfstiftung, Wien, Österreich

    Mag. Dr. Robert Terkola

  6. Apotheke LKH-Univ.-Klinikum Graz, Wien, Österreich

    Mag. Sabine M. Wassertheurer

Authors
  1. Dr. Ines Mader
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mag. pharm. Patrizia Fürst-Weger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Univ.-Prof. Dr. Robert M. Mader
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mag. pharm. Dr. Elisabeth I. Semenitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mag. Dr. Robert Terkola
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mag. Sabine M. Wassertheurer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Wien

About this chapter

Cite this chapter

Mader, I., Fürst-Weger, P., Mader, R.M., Semenitz, E.I., Terkola, R., Wassertheurer, S.M. (2002). 5-Fluorouracil (z.B. 5-Fluorouracil „Ebewe“). In: Paravasation von Zytostatika. Springer, Vienna. https://doi.org/10.1007/978-3-7091-3799-4_29

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-3799-4_29

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-3800-7

  • Online ISBN: 978-3-7091-3799-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation